Shanghai can lower bond fees faster than it can build liquidity
The legal framework and reported rebates can restart issuance, but issuer diversity and secondary trading will decide whether the venue becomes a market.
K4invest / Latest news
Markets
Expert insights to improve your financial decisions
The cash leg will decide whether Europe’s tokens become a market
Pontes can give tokenised securities safe settlement in central-bank money. Liquidity still depends on Appia solving standards, law and fragmentation.
Trump's 1,051 trades make the disclosure bands visible
The June filing documents 1,051 transactions, but value ranges, missing prices and absent position data make it an activity log rather than a precise portfolio map.
Alphabet has entered Berkshire's core allocation circle
Berkshire's Alphabet stake reached $37.8 billion through market holdings and a direct placement. The filings measure concentration, while governance evidence separates idea origination from final authority.
Unitree's debut priced public scarcity before robot deployment
Unitree raised at 150.80 yuan, while a 10% listed slice closed at 845 yuan and repriced the whole company far beyond the cash it received.
A trading-card grade is a price oracle with a custody problem
A forged-grade conviction shows why a certification lookup is only one control in a market that also needs physical inspection and traceable custody.
Alphabet's Australian bond is a distribution choice, not a currency bet
Alphabet's record A$5.5 billion sale widens its funding network; swaps and future disclosures will reveal the actual economics.
Sweepstakes casinos are losing the economics of one national market
State enforcement now reaches payments, game content and affiliates, eroding the operating leverage behind a national dual-currency product.
AI can reach Treasury yields only through the real economy
AI investment can affect growth, inflation, power demand, financing, and productivity, but a higher Treasury yield does not identify which channel moved.
The yen intervention bought a price move, not a new equilibrium
Coordinated buying moved the yen sharply, but durability depends on yield incentives, policy credibility, and evidence of what officials actually did.
Biotech prediction markets can price an endpoint, not validate it
Contracts on clinical trials isolate a single outcome that biotech shares cannot. Their prices will be useful only if liquidity, disclosure, settlement, and insider controls earn trust over time.
Devolver's delisting sells liquidity to buy operating patience
The proposed AIM exit could save money and suit uneven game cycles, but the first tender covers only 4.71% of shares and leaves others with weaker liquidity and governance.